SCHOLAR ROCK HOLDING CORPORATION (SRRK) Debt / Equity
- 2024-06-30: Debt/Equity Ratio 0.37.
- 2024-03-31: Debt/Equity Ratio 0.27.
- 2023-12-31: Debt/Equity Ratio 0.22.
- 2022-09-30: Debt/Equity Ratio 0.17.
Complete source-backed debt/equity ratio history.
- Available history
- 2021-12-31 to 2024-06-30
- Data captured
Historical Debt/Equity Ratio
| Date | Debt/Equity Ratio |
|---|---|
| 2024-06-30 | 0.37 |
| 2024-03-31 | 0.27 |
| 2023-12-31 | 0.22 |
| 2022-09-30 | 0.17 |
| 2022-06-30 | 0.15 |
| 2022-03-31 | 0.29 |
| 2021-12-31 | 0.29 |
Annual Debt/Equity Ratio
| Date | Debt/Equity Ratio |
|---|---|
| 2023-12-31 | 0.22 |
| 2021-12-31 | 0.29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |